BidaskClub downgraded shares of Stemline Therapeutics (NASDAQ:STML) from a buy rating to a hold rating in a report released on Wednesday.
A number of other analysts also recently issued reports on STML. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a buy rating in a research note on Monday, March 19th. Zacks Investment Research downgraded Stemline Therapeutics from a hold rating to a sell rating in a research note on Friday, February 9th. Finally, ValuEngine raised Stemline Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Stemline Therapeutics currently has an average rating of Hold and a consensus target price of $31.33.
STML stock opened at $14.35 on Wednesday. Stemline Therapeutics has a 52 week low of $7.30 and a 52 week high of $18.75.
In other news, CEO Ivan Bergstein sold 3,820 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $15.80, for a total transaction of $60,356.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kenneth Hoberman sold 14,040 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $13.93, for a total value of $195,577.20. The disclosure for this sale can be found here. Insiders sold a total of 156,418 shares of company stock valued at $2,628,131 over the last ninety days. Corporate insiders own 16.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in STML. Northern Trust Corp grew its holdings in shares of Stemline Therapeutics by 18.0% during the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after purchasing an additional 41,898 shares during the period. Vanguard Group Inc. grew its holdings in shares of Stemline Therapeutics by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after purchasing an additional 38,615 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Stemline Therapeutics by 74.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 51,578 shares during the period. Voya Investment Management LLC purchased a new position in shares of Stemline Therapeutics during the 2nd quarter worth $102,000. Finally, State Street Corp grew its holdings in shares of Stemline Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock worth $3,179,000 after purchasing an additional 35,116 shares during the period. Institutional investors and hedge funds own 52.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3296381/bidaskclub-lowers-stemline-therapeutics-stml-to-hold.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.